AU
UK
CA
NZ
IND
US
Wave Life Sciences (NASDAQ:WVE) made headlines on Monday after announcing interim results from a Phase 1 clinical trial of its investigational weight loss drug, WVE-007. The drug demonstrated a 4.5% reduction in total body fat over three months, compared to no meaningful change in …
Regencell Bioscience Holdings Ltd (NASDAQ:RGC) closed atUSD 16.07on December 05, reflecting a rise of17.0c (1.1%)from the prior session. The move compared with theNASDAQ-100, which added85.5 points (0.3%)during the day. The stock’s relative price increase of0.7%against the index placed it ahead of the broader benchmark …
Gilead Sciences (NASDAQ:GILD), through its Kitesubsidiary, presented new data reinforcing the performance and consistency of its CAR T-cell therapy, Yescarta, in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). The analysis combined four-year outcomes from the Phase 3 ZUMA-7 trial and two-year …
Ascentage Pharma Group International (NASDAQ:AAPG) presented new clinical results from its Phase Ib/II trial evaluating Lisaftoclax (APG-2575) in combination with azacitidine during the 67th American Society of Hematology Annual Meeting. The trial focused on patients with newly diagnosed or prior venetoclax-exposed myeloid malignancies, including …
HUTCHMED Limited(NASDAQ:HCM)announced renewed inclusion of three key oncology therapies—ELUNATE®, ORPATHYS® and SULANDA®—in China’s updated National Reimbursement Drug List (NRDL), effective January 1, 2026. The renewed listing follows a contract renewal with the National Healthcare Security Administration, reflecting continued recognition of these therapies within China’s …
Structure Therapeutics (NASDAQ:GPCR) announced that it will publish topline results from its ACCESS clinical program evaluating aleniglipron, the company’s once-daily oral GLP-1 receptor agonist for obesity, before the market opens on December 8, 2025. Anticipation is high as the company works to advance an …
Immix Biopharma (NASDAQ:IMMX) announced promising Phase 2 clinical results for its sterically optimized CAR-T candidate NXC-201 during an oral presentation at ASH 2025. Led by Dr. Heather Landau of Memorial Sloan Kettering Cancer Center, the data highlighted a 75% complete response rate in relapsed/refractory …
Eli Lilly and Company (NYSE:LLY) has released pivotal data from the Phase 3 BRUIN CLL-314 trial, marking the first randomized head-to-head comparison between covalent and non-covalent BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma. Jaypirca (pirtobrutinib), Lilly’s highly selective, reversible BTK inhibitor, …
Rigel Pharmaceuticals (NASDAQ:RIGL) presented updated data from its ongoing Phase 1b study evaluating R289, an oral prodrug of the dual IRAK1/4 inhibitor R835, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome. The findings were shared during an oral session at the 67th …
Incyte (NASDAQ:INCY) has announced that the U.S.FDAhas granted Breakthrough Therapy designation to INCA033989, the company’s first-in-class monoclonal antibody designed to target mutant calreticulin (mutCALR). The designation applies to patients with essential thrombocythemia who carry a Type 1 CALR mutation and are resistant or intolerant …
Please wait processing your request...